Healthcare
LAV, Arch lead $100m round for China's SciNeuro
SciNeuro Pharmaceuticals, a China and US-based drug developer specializing in treatments for central nervous system (CNS) disorders, has announced its formal launch with a $100 million funding round.
Israel's OTV raises $170m, plans Asia expansion
OTV, an Israeli VC firm focused on digital health, has closed its latest fund at $170 million, opened a China office, and appointed a new head of Asia to spearhead an expansion in the region.
Everstone buys Indian pharma ingredients player
Everstone Group has acquired a controlling stake in Calibre, an Indian ingredients supplier for the pharmaceutical and nutrition industries, for an undisclosed sum.
Deal focus: Huaxing gives overseas LPs taste of China medtech
In addition to raising $213 million for its latest renminbi-denominated fund, Huaxing Healthcare Capital sourced $230 million from co-investors for a succession deal in China’s orthopedics space
Japan's MedVenture closes second fund at $95m
MedVenture Partners, a Japanese VC firm focused on medical devices, has closed its second fund with JPY9.9 billion ($95 million) in commitments.
3W leads $43m Series E for China's CANbridge
Hong Kong’s 3W Fund Management has led a $43 million Series E round for CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses cancer and rare diseases.
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
NZ Super, OTPP buy New Zealand pathology business
New Zealand Superannuation Fund (NZ Super) and Ontario Teachers’ Pension Plan (OTPP) have completed a NZ$550 million ($387 million) carve-out of Healthscope’s New Zealand pathology services business.
JD Health targets largest Chinese PE-backed IPO in two years
JD Health, a Chinese online-to-offline healthcare business that raised around $1.9 billion from private investors after it spun out from JD.com, is looking to raise HK$26.9 billion ($3.48 billion) in its Hong Kong IPO.
Chinese vision therapy start-up Elumninex raises $50m
Chinese eye disease specialist Elumninex Biosciences has raised a $50 million Series A round led by GL Ventures, Lilly Asia Ventures (LAV), and Quan Capital.
PE-backed Antengene trades flat after $359m HK IPO
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
Sequoia, Matrix back $200m Series A for China’s D3 Bio
D3 Bio, a Chinese drug developer that studies and specifically targets areas where existing approaches to care are not delivering satisfactory outcomes, has raised $200 million in Series A funding.
KKR buys majority stake in New Zealand animal health business
KKR has acquired Argenta, a New Zealand-based animal health services provider, for an undisclosed sum.
Goldman invests $150m in India biosimilars business
Goldman Sachs has invested INR11.2 billion ($150 million) in Biocon Biologics, the biosimilars business of Indian pharmaceuticals manufacturer Biocon, at a post-money valuation of $3.94 billion.
Cell analysis player Cytek raises $120m Series D
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.
Q&A: Investcorp's Duncan Zheng
Duncan Zheng, head of China private equity at Investcorp, observes that COVID-19 dislocation has created some timely inroads as the firm’s broader expansion agenda ramps up
China's JW Therapeutics trades up after $300m Hong Kong IPO
JW Therapeutics, a private equity-backed Chinese drug developer specializing in CAR T-cell therapies that engineer immune cells to fight cancers, has raised HK$2.33 billion ($300 million) through a Hong Kong IPO.
China's CARsgen raises $186m Series C
Chinese biotech player CARsgen Therapeutics has raised $186 million in Series C funding led by Loyal Valley Capital.
Eight Roads adds healthcare partner in China
Eight Roads Ventures has recruited Xin Liu, formerly of Greater Pacific Capital, as a partner in its China team.
China biotech player Genecast raises $149m Series E
Genecast Biotechnology, a Chinese gene sequencing and precision diagnostics company, has closed a RMB1 billion ($149 million) Series E funding round led by China Structural Reform Fund.
China's LianBio receives $310m round
LianBio, a Chinese biotech start-up incubated earlier this year by life sciences investor Perceptive Advisors, has raised $310 million from a group featuring BlackRock.
China biotech player Gracell raises $100m Series C
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
Infratil, Morrison bid $524m for Australia radiology business
New Zealand infrastructure investors Infratil and HRL Morrison have offered to acquire a 75% stake in Australia-based radiology business Qscan for an enterprise valuation of A$735 million ($524 million), facilitating an exit for Quadrant Private Equity.
China O2O medicine platform raises $150m
Chinese online-to-offline (O2O) medicine retailer Dingdang Kuaiyao has raised RMB1 billion ($150 million) in an extended Series B round featuring Dragon Gate Investment Partners.